MX2022005034A - Combinacion farmaceutica y uso de la misma. - Google Patents

Combinacion farmaceutica y uso de la misma.

Info

Publication number
MX2022005034A
MX2022005034A MX2022005034A MX2022005034A MX2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
present disclosure
disclosure relates
cancer
colon cancer
Prior art date
Application number
MX2022005034A
Other languages
English (en)
Spanish (es)
Inventor
Juan Zhang
Original Assignee
Cstone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Suzhou Co Ltd filed Critical Cstone Pharmaceuticals Suzhou Co Ltd
Publication of MX2022005034A publication Critical patent/MX2022005034A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2022005034A 2019-11-11 2020-11-11 Combinacion farmaceutica y uso de la misma. MX2022005034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019117155 2019-11-11
PCT/CN2020/128083 WO2021093764A1 (en) 2019-11-11 2020-11-11 Pharmaceutical combination and use thereof

Publications (1)

Publication Number Publication Date
MX2022005034A true MX2022005034A (es) 2022-05-16

Family

ID=75911807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005034A MX2022005034A (es) 2019-11-11 2020-11-11 Combinacion farmaceutica y uso de la misma.

Country Status (11)

Country Link
US (1) US20220387417A1 (https=)
EP (1) EP4031179A4 (https=)
JP (1) JP2023500385A (https=)
KR (1) KR20220103961A (https=)
CN (1) CN114901309A (https=)
AU (1) AU2020383580A1 (https=)
BR (1) BR112022009042A2 (https=)
CA (1) CA3160526A1 (https=)
IL (1) IL292646A (https=)
MX (1) MX2022005034A (https=)
WO (1) WO2021093764A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450616A3 (en) * 2016-09-21 2025-01-01 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (pd-1)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
EP4450616A3 (en) * 2016-09-21 2025-01-01 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (pd-1)
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
KR102655301B1 (ko) * 2017-04-06 2024-04-08 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
CN110536694A (zh) * 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
CN109731019B (zh) * 2019-03-07 2021-07-16 康赋葆(深圳)生物医药科技有限公司 一种具有化疗增效作用的组合物，包括组成、制备及应用
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法

Also Published As

Publication number Publication date
BR112022009042A2 (pt) 2022-10-11
JP2023500385A (ja) 2023-01-05
CN114901309A (zh) 2022-08-12
AU2020383580A1 (en) 2022-05-12
US20220387417A1 (en) 2022-12-08
EP4031179A1 (en) 2022-07-27
CA3160526A1 (en) 2021-05-20
KR20220103961A (ko) 2022-07-25
IL292646A (en) 2022-07-01
WO2021093764A1 (en) 2021-05-20
EP4031179A4 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MX2019003938A (es) Compuestos espirociclicos.
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
NZ795278A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
PH12019550224A1 (en) Antitumoral compounds
AU366476S (en) Bottle
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX379622B (es) Compuestos espirociclicos
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2017014436A (es) Compuestos biciclicos.
MY209035A (en) Tricyclic compounds and their use
GEAP201814266A (en) Pyrazines modulators of gpr6
WO2019098811A3 (ko) Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MY200161A (en) Bacteria for targeting tumors and treating cancer
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2022005034A (es) Combinacion farmaceutica y uso de la misma.